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Background: Intraperitoneal (i.p.) models that accurately mimic the feature behavior of human ovarian cancer are
required to investigate the pathology and therapeutics of the disease. However, established i.p. models which are
well-characterized and reliable are few. The purposes of this study are to establish a representative mice i.p. model
of the disease and to analyze the consequent pathology.
Methods: Fresh tumor cells fiom the ascites of patient were injected into female NOD/SCID mice intraperitoneally.
Histology, Cytogenetic, immunohistochemistry,tumor markers of CA125,AFP, CA-199 and CEA were used to analyze
the model.
Results: The mice developed marked abdominal distention within 6 months after inoculated with tumor cells from a
patient with epithelial ovarian carcinoma. The mice developed clinically evident intraperitoneal tumors and massive
ascites containing numerous tumor cells in clumps. CA125 level in our model was high in both serum and ascites
supernatants, while levels of other tumor markers, such as AFP, CA-199 and CEA, were normal. Cytogenetic analysis and
immunohistochemical staining confirmed its characteristics resembling human epithelial ovarian tumor.
Conclusions: The model described in this paper accurately mimics the features of ovarian tumor, which may be useful
for evaluation of new therapeutics.
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Ovarian cancer is the leading cause of death among gyne-
cologic tumors with a death toll up to 13850 in the USA
by 2010 [1]. Epithelial ovarian cancer (EOC) accounts for
over 90% of all ovarian malignancies. Its high mortality is
attributable to the fact that 75% of the patients are not
diagnosed until the advanced stage. Although the majority
of the patients respond to initial chemotherapy after a pri-
mary debulking surgery, most eventually experience recur-
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reproduction in any medium, provided the orthe development of well-characterized and reliable models
is crucial for evaluating efficacy of novel therapeutics,
which may help improve patient survival.
In developing an in vivo model of human ovarian neo-
plasia, it is critical to ensure that the model mimics the
behavior of ovarian tumor in patient accurately. Re-
search teams have attempted relevant models employing
subcutaneous (s.c.) and intraperitoneal (i.p.) xenografts
in immunodeficient mice [3-16], where only the i.p.
models were in line with the clinical manifestations in
the advanced stage given the carcinomatosis in the peri-
toneal cavity with large volumes of ascites. Further more,
such models seemed clinically useful in demonstrating
efficacy of the intraperitoneal therapies being tested,
which was hardly the case with the s.c. models. Most of
the models commonly used in ovarian cancer research
are based on established cell lines. However, it is found
that, compared with the cell lines, only xenografts estab-
lished directly from fresh human ovarian tumor tissuesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expression [12], as may be attributed to the fact that the
cell lines could have changed their protein expression pat-
terns and lost the heterogenetic characteristics of human
cancer through long-term in vitro culturing.
Serum tumor markers also seem useful in the manage-
ment of several types of ovarian tumor. For example,
CA125, measurable in the serum, is routinely used as a
diagnostic biomarker of ovarian cancer in clinical set-
tings, which, however, due to its low sensitivity in the
early stage, tends to make better sense for monitoring
tumor progression and response to therapy. Its use for
evaluating therapeutic efficacy has been attempted in a
few studies [17,18].
In our study, we employed the NOD/SCID mice and
fresh tumor cells, and established a novel reproducible
xenograft model of ovarian cancer, which is transplant-
able and is characterized by its close mimic of the pro-
gressive massive ascites, extensive intra-abdominal




The patient was a 53-year-old post-menopausal woman
presenting with a 2-month history of abdominal disten-
tion with a mass in the right adnexa. Cytological study
of the ascites indicated presence of adenocarcinoma
cells, with a serum CA125 level of 1364 U. She received
intraperitoneal chemotherapy with Thiotepa twice (1st:
30mg, 2nd: 20mg) before surgery (cyto-reductive sur-
gery, extrafascial hysterectomy, bilateral adnexectomy,
omentectomy, appendectomy). Poorly differentiated
serous adenocarcinomas of the ovary (stage FIGO IIIC)
were pathologically confirmed. Informed consent was
acquired from the patient.
Animals
Four- to six-week-old female NOD/SCID mice (pur-
chased from Beijing HFK Bio-Technology Co. Ltd.,
Beijing, China) were housed in sterile micro-isolators
(5 mice per cage). Feeding and water were given ad libi-
tum. All procedures were performed under sterile condi-
tions in a laminar flow hood. The animals were
monitored daily for general health status. All animal
experiments described in this study were approved by
the Institutional Animal Care and Use Committee of
Sichuan University.
Heterotransplantation and in vivo Passaging
A tumor specimen (ascites) was collected and sterilely
transported on ice to the laboratory. The ascites was
centrifuged at 300G for 5min. The cell pellet was imme-
diately intraperitoneally injected into the NOD/SCIDmice. The number of tumor cells from the patient
inoculated into the two mice was 5x10E7.
When the animals had marked abdominal distensions,
their ascites was collected from the tumor-bearing mice,
and directly injected into the next mice. The mice were
then monitored daily for general health status as well as
the degree of abdominal extension before another passa-
ging. Xenografts were established within 6 months after
heterotransplantation in both mice.As passaging contin-
ued, the number of tumor cells we used was 1x10E7.
The peritoneal cavity of each animal was examined. Tis-
sues and organs suspected of being affected by tumor
were eventually harvested for histological examinations.
Freezing storage of xenograft tumor
After the animals were sacrificed, ascites was collected
and centrifuged at 300G for 5min. The pellet was sus-
pended in cold freezing media, consisting of DMEM
with 8% DMSO and 20% fetal bovine serum (FBS). The
cells were then transferred to liquid nitrogen for long-
term storage. For retransplantation, the tumor suspen-
sion underwent a rapid thaw at 37°C, and was diluted in
10ml of DMEM without FBS. Then it was centrifuged,
and intraperitoneally injected into the mice.
Immunohistochemistry
Tumors in the peritoneal cavity were fixed in 4% neutral
buffered formalin, and processed for histological exam-
ination. The fixed samples were embedded in paraffin,
5μ-thick sections were cut, and H-E staining was ap-
plied. Cell suspensions from ascites were cyto-centri-
fuged, and smear was fixed with cold acetone.
Endogenous peroxidase activity was then blocked with
3% hydrogen peroxide in PBS for 10min. The samples
were subsequently rinsed with PBS for 5min. All tissues
were blocked with BSA for 20min at room temperature.
Primary monoclonal antibodies to vimentin (dilution
1:300), pan-cytokeatin (dilution 1:400), EMA (dilution
1:500), P53 (dilution 1:300), MMP-2 (dilution 1:300) (all
supplied by Wuhan Boster Bio-Engineering Co. Ltd.,
Wuhan, China), and CA125 (dilution 1:400) (supplied by
Beijing Zhongshan Golden Bridge Biotechnology Co.
Ltd., Beijing, China) were used. Sections were incubated
with the antibodies overnight at 4°C following three 5-
min washes with PBS, then incubated with biotinylated
secondary antibody at 37°C for 20min, and finally incu-
bated with streptavidin-biotin-horse radish peroxidase
complex at 37°C for 20min. The sections were then
developed with diaminobenzidine (DAB) as a substrate.
Cellular nuclei were counterstained with hematoxylin.
All operations followed the manufacturers’ recommen-
dations. Absent primary antibody during processing was
used as blank control. Immunostaining was semi-
quantitative as described [19].
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Whole blood and ascites specimens were collected from
the tumor-bearing mice, and centrifuged for 10min. The
supernatants were isolated and stored at −20°C for sub-
sequent analysis. Levels of CA125, CA199, AFP and
CEA were determined.
Cytogenetics
Ascites specimens were collected and centrifuged. Cell
pellet was resuspended in DMEM supplemented with
10% heat-inactivated fetal calf serum (FCS), and exposed
to 0.5μg/ml demecolcine (Colcemid) for 2 hours. Cyto-
genetic analysis was accomplished by G-banding using a
conventional Giemsa staining protocol [20]. Briefly,
tumor cells were harvested and incubated in 75mM po-
tassium chloride at 37°C. Then they were fixed with 25%Figure 1 (A) Female NOD/SCID mice with abdominal distention after
(B) Presence of milky ascites in mice; (C) Large, crowded clumps of cells in
diaphragmatic tumor deposits and deposits on liver surface; (F) Reproducti
Arrowhead indicates metastatic tumor. O-ovary; S-fallopian tube; U-uterus.acetic acid in anhydrous methanol twice. The slides were
trypsinized and stained with 10% Giemsa, and 35 meta-
phase spreads were karyotyped.
Results
Growth of human ovarian tumors in scid mice
Tumor cells in the ascites from the patient with poorly
differentiated ovary papillary serous adenocarcinoma
were injected into the peritoneal cavities of female
NOD/SCID mice. Xenografts were established within 6
months after heterotransplantation. As passaging contin-
ued, the time to achieve a clinically evident disease
decreased to 1–2 months. All mice eventually developed
visible abdominal swelling (Figure 1A) and yellowish
pale ascites (Figure 1B). The volume of ascites was gen-
erally 4 to 8ml per mouse. Abundant cells of clinicalinjection of ascites tumor cells. Left image is non-injected control;
ascites; (D) Mesentery invaded by tumor tubercles; (E) Sub-
ve system affected by tumor. Left image is non-injected control.
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cytological examination of the ascites (Figure 1C). The
malignant features of the cells were confirmed by
high nuclear-cytoplasmic ratio, nuclear multiforme
and predominant nucleoli; and these histological
characteristics were documented in different mouseFigure 2 Immunohistochemical staining and Karyotyping profile of xe
(B) PCNA; (C) P53; (D) Vimentin; (E) CA125; (F) Pan-cytokeatin; (G) MMP-2 (x
of chromosomes generally between 54 and 60, mostly triploidy with structgenerations. The mean viable tumor cell yield from
ascites was approximately 1.5 × 109 cells per mouse.
The malignant cells in the ascites could be reprodu-
cibly maintained and directly passaged to subsequent
hosts. The cells have been serially transplanted 8
times to date. This model may be reproduced usingnograft tumors from ascites of the sixth generation. (A) EMA;
400); (H) Karyotyping profile of malignant cells from ascites. Number
ural abnormalities.
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of histological changes.
Metastatic pattern
The metastatic pattern was investigated, where similar
results were noted in different generations. In the
advanced stage of this model, the mesentery was most
frequently invaded by tumor tubercles (Figure 1D).
Deposits of tumor cells were found on the surfaces
of peritoneal organs, such as the sub-diaphragmatic
and liver linings, which replicated the initial mice
(Figure 1E). The reproductive system was severely
affected by tumor cells (Figure 1F). Severe unilateral or
bilateral ovarian pathogenesis was found in 75% of the
animals in our model. In most cases, the histomorphol-
ogy and cytology of ovary changed as the condition
developed from crowding and displacement to complete
invasion. All suspicious areas were biopsied. No evi-
dence of extraperitoneal spread was noted.
Cytogenetics
Human female origin of the established xenograft model
was confirmed by cytogenetic analysis. Thirty-five
banded metaphases were analyzed. Chromosome num-
ber ranged from 54 to 60 (median: 58), mainly trisomy
(Figure 2H).
Immunohistochemistry
To analyze the histopathology of the tumor cells in the
ascites, immunohistochemical staining was performed to
determine expression of epithelial membrane antigen
(EMA), Pan-cytokeatin, vimentin (VIM), PCNA, P53,
CA125 and MMP-2. The results are given in Table 1
and Figure 2. It’s found that there is no significant
changes in comparison with the first generation (the pic-
tures were showed as Additional file 1: Figure S3).
Tumor makers in serum and ascites
In analyzing the CA125, CA199, CEA and AFP levels in
serum and ascites, we found that only the CA125 levelTable 1 Immunohistochemical markers of
heterotransplanted tumor cells from ascites of the sixth
generation
Marker Result Method







* IHC: Immunohistochemical staining.rose in both serum and ascites in the tumor-laden mice.
The serous CA125 level ranged 293.4-1024.4U/ml.
Supernatant of the malignant ascites was found to con-
tain 484.2-3800U of CA125 per ml. The normal serous
CA125 level (< 11 U/ml) was documented in all healthy
control mice.Discussion
We established a reproducible murine xenograft model
of ovarian carcinoma employing tumor cells harvested
from the ascites of an ovarian cancer patient, where the
cells may be reproducibly maintained and directly pas-
saged to subsequent hosts. This model requires no se-
lective methods before intraperitoneal growth such as
enzymatic digestion, selective anchorage-independent
growth, and subcutaneous inoculation [7,12,15,16]. As a
result, the unwanted implications of the manipulations
were avoided.
The tumor cells from the ascites were hyperchromatic
for CA125 antigen, Pan-cytokcratin and epithelial anti-
gen, which confirmed it to be epithelial differentiation
[8]. MMP-2 is believed to be involved in two aspects of
the ovarian cancer spread process: It helps tumor cells
penetrate the basement membrane of the ovary to in-
vade the stroma [21], and may enable the tumor cells to
detach from the epithelial surface and migrate into the
peritoneal cavity [22,23]. It is reported that the rate of
MMP2 expression in ovarian cancer is high and irrele-
vant with either clinical staging or histological typing
[24]. One possible explanation was the grave malignance
of ovarian cancer. In our model, we also noted tumor
cells with high MMP-2 expression. P53 mutation occurs
early in the progression of ovarian cancer [25], which is
found in some 50% or more of advanced serous adeno-
carcinomas while rarely noted in earlier stages [26-28].
In this model, tumor cells show intense expression of
p53, consistent with the previous reports.
We examined the transplanted tumors in ascites at dif-
ferent passages, and found that the characteristics did
not change from one generation to another. As a result,
this may offer an unlimited in vivo supply of stable
tumor cells, which may be of great value for ensuring re-
producibility and reliability of research results. In the fu-
ture, we may establish similar models of other ovarian
cancer subtypes for furthering our knowledge on the
disease.
In this model, we examined the CA125, CA199, CEA
and AFP levels in blood and ascites, only to find that the
CA125 level alone rose in the tumor-bearing mice. This
makes a possibility where CA125 may be used as a bio-
marker in the model, similar to its clinical application,
for prognosis prediction and therapeutic evaluation in
future studies.
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This novel model of ovarian cancer, which mimics
human carcinosis accurately, appears simple and repro-
ducible. It may also be instrumental for culturing ovar-
ian carcinomas in vivo, hence as an unlimited source of
ovarian cancer cells for research purposes. Great merit is
seen in our model for evaluating new therapeutics given
its CA125 level matching the human situation closely.Additional file
Additional file 1: Immunohistochemical staining a of xenograft
tumors from ascites of the first generation. (A1) EMA; (B1) PCNA; (C1)
P53; (D1) Vimentin; (E1) CA125; (F1) Pan-cytokeatin; (G1) MMP-2 (x400).
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